<?xml version="1.0" encoding="UTF-8"?>
<p id="p0155">One of the recently approved anti-HIV combinations, Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide), is currently under phase 3 and 4 clinical trials for HIV-HBV coinfection (NCT03547908 and NCT03797014). The primary objective of this study is to evaluate the efficacy and safety of a fixed-dose combination in adults coinfected with HIV-1 and HBV. 
 <xref rid="tbl2" ref-type="table">Table 2</xref> presents the most commonly used combinations of NRTIs, NNRTIs and HIV integrase inhibitors, and 
 <xref rid="fig2" ref-type="fig">Fig. 2</xref> shows the structures of the compounds listed in 
 <xref rid="tbl2" ref-type="table">Table 2</xref> grouped according to their chemical characteristics and molecular targets.
</p>
